GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daiichi Sankyo Co Ltd (OTCPK:DSNKY) » Definitions » Shiller PE Ratio

Daiichinkyo Co (Daiichinkyo Co) Shiller PE Ratio : (As of Apr. 26, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Daiichinkyo Co Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Daiichinkyo Co Shiller PE Ratio Historical Data

The historical data trend for Daiichinkyo Co's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Daiichinkyo Co Shiller PE Ratio Chart

Daiichinkyo Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 52.54 68.05 52.56 87.60 -

Daiichinkyo Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 87.60 78.93 69.23 63.36 -

Competitive Comparison of Daiichinkyo Co's Shiller PE Ratio

For the Drug Manufacturers - General subindustry, Daiichinkyo Co's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Daiichinkyo Co's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Daiichinkyo Co's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Daiichinkyo Co's Shiller PE Ratio falls into.



Daiichinkyo Co Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Daiichinkyo Co's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Daiichinkyo Co's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.129/107.2000*107.2000
=0.129

Current CPI (Mar. 2024) = 107.2000.

Daiichinkyo Co Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 0.093 98.000 0.102
201409 0.133 98.500 0.145
201412 0.206 97.900 0.226
201503 0.863 97.900 0.945
201506 0.134 98.400 0.146
201509 0.144 98.500 0.157
201512 0.160 98.100 0.175
201603 -0.120 97.900 -0.131
201606 0.141 98.100 0.154
201609 0.089 98.000 0.097
201612 0.169 98.400 0.184
201703 -0.151 98.100 -0.165
201706 0.132 98.500 0.144
201709 0.023 98.800 0.025
201712 0.171 99.400 0.184
201803 -0.057 99.200 -0.062
201806 0.112 99.200 0.121
201809 0.092 99.900 0.099
201812 0.159 99.700 0.171
201903 0.068 99.700 0.073
201906 0.206 99.800 0.221
201909 0.101 100.100 0.108
201912 0.329 100.500 0.351
202003 -0.025 100.300 -0.027
202006 0.152 99.900 0.163
202009 0.096 99.900 0.103
202012 0.120 99.300 0.130
202103 0.002 99.900 0.002
202106 0.167 99.500 0.180
202109 0.129 100.100 0.138
202112 0.146 100.100 0.156
202203 -0.120 101.100 -0.127
202206 0.073 101.800 0.077
202209 0.144 103.100 0.150
202212 0.110 104.100 0.113
202303 0.088 104.400 0.090
202306 0.210 105.200 0.214
202309 0.141 106.200 0.142
202312 0.241 106.800 0.242
202403 0.129 107.200 0.129

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Daiichinkyo Co  (OTCPK:DSNKY) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Daiichinkyo Co Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Daiichinkyo Co's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Daiichinkyo Co (Daiichinkyo Co) Business Description

Traded in Other Exchanges
Address
3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, JPN, 103-8426
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2021, approximately half of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first U.S approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.